Cell therapy (CAR-T) · Kills target cells, directed at CD19 · developed by CRISPR Therapeutics
Evoncabtagene pazurgedleucel is a preparation of allogeneic T lymphocytes transduced with a chimeric antigen receptor directed against CD19 and gene-edited with CRISPR-Cas9 to remove the endogenous T-cell receptor. The CAR-T cells recognize and kill CD19-positive B-cell malignancies, and it is studied in B-cell lymphomas and B-cell acute lymphoblastic leukemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04035434 | Phase 1/2 | B-cell Malignancy | Terminated | CRSP |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Adult B Cell ALLB-cell LymphomaB-cell MalignancyNon-Hodgkin Lymphoma
Updated Nov 8, 2026. Something wrong or missing? Report it on the CRSP page.
See CRSP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CRSP catalysts and pipeline →